These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 11038028)
1. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ferreri AJ; Reni M; Villa E Ann Oncol; 2000 Aug; 11(8):927-37. PubMed ID: 11038028 [TBL] [Abstract][Full Text] [Related]
2. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E Oncology; 2001; 60(2):134-40. PubMed ID: 11244328 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Reni M; Ferreri AJ; Guha-Thakurta N; Blay JY; Dell'Oro S; Biron P; Hochberg FH Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):419-25. PubMed ID: 11567816 [TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. Reni M; Mazza E; Foppoli M; Ferreri AJ Cancer Lett; 2007 Dec; 258(2):165-70. PubMed ID: 17993246 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Reni M; Ferreri AJ Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
8. The role of additional radiotherapy for primary central nervous system lymphoma. Zacher J; Kasenda B; Engert A; Skoetz N Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009211. PubMed ID: 24931518 [TBL] [Abstract][Full Text] [Related]
9. Primary CNS lymphoma in immunocompetent patients from 1989 to 2001: a retrospective analysis of 164 cases uniformly diagnosed by stereotactic biopsy. Feuerhake F; Baumer C; Cyron D; Illerhaus G; Olschewski M; Tilgner J; Ostertag CB; Volk B Acta Neurochir (Wien); 2006 Aug; 148(8):831-8; discussion 838. PubMed ID: 16791439 [TBL] [Abstract][Full Text] [Related]
10. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456 [TBL] [Abstract][Full Text] [Related]
11. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274 [TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M; J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of polyglutamylation in primary central nervous system lymphoma. Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458 [TBL] [Abstract][Full Text] [Related]
14. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690 [TBL] [Abstract][Full Text] [Related]
15. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Reni M; Ferreri AJ; Garancini MP; Villa E Ann Oncol; 1997 Mar; 8(3):227-34. PubMed ID: 9137790 [TBL] [Abstract][Full Text] [Related]
18. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study. Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957 [TBL] [Abstract][Full Text] [Related]
19. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]